Jingjia Yu1, Wei Pan2, Ruizheng Shi2, Tianlun Yang2, Yuanjian Li3, Guolong Yu2, Yongping Bai2, Edward H Schuchman4, Xingxuan He5, Guogang Zhang6. 1. The State Key Laboratory of Medical Genetics, Xiangya Medical School, Central South University, Changsha, Hunan, China. 2. Department of Cardiovascular Medicine, Xiangya Hospital, Central South University, Changsha, China. 3. Department of Pharmacology, School of Pharmaceutical Sciences, Central South University, Changsha, China. 4. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 5. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: xingxuan.he@mssm.edu. 6. Department of Cardiovascular Medicine, Xiangya Hospital, Central South University, Changsha, China. Electronic address: xyzgg2006@sina.com.
Abstract
BACKGROUND: Ceramide is involved in apoptosis, inflammation, and stress responses, which are among the pathogenic components of chronic heart failure (CHF). However, no one has documented the levels of ceramide itself in CHF or determined its potential prognostic value. METHODS: In this study we recruited patients with heart failure consecutively from the hospital, of whom 423 stable patients were eventually selected to participate in this study after an observation period of at least 3 months after hospital discharge. All patents were followed up for all-cause death to December 31, 2013. RESULTS: Plasma ceramide levels were increased stepwise with New York Heart Association functional class (I, 5.32 ± 1.98; II, 5.81 ± 1.63; III, 6.14 ± 2.14; IV, 6.66 ± 2.61 ng/mL). During a mean follow-up of 4.4 years (interquartile range: 3.5-5.3 years), a total of 200 CHF patients died. The optimal threshold value of ceramide was 6.05 ng/mL. Ceramide levels as continuous and as dichotomous variables are risk factors for mortality in CHF (adjusted hazard ratio, 1.31; 95% confidence interval, 1.16-1.47; P < 0.001 and adjusted hazard ratio, 2.07, 95% confidence interval, 1.53-2.81; P < 0.001, respectively). When ceramide levels were combined with conventional CHF risk factors, the area under the curve increased from 0.68 (0.63-0.72) to 0.72 (0.68-0.76); P = 0.047. The continuous net reclassification index and integrated discrimination improvement index were 17.2% (5.0-29.9%; P = 0.027) and 0.04 (0.01-0.08; P = 0.020), respectively. CONCLUSIONS: Plasma ceramide levels were increased and correlated with the severity of CHF, and were an independent risk factor of mortality in patients with CHF and reduced left ventricular systolic function. Ceramide levels might provide additional predictive value after conventional risk assessment.
BACKGROUND:Ceramide is involved in apoptosis, inflammation, and stress responses, which are among the pathogenic components of chronic heart failure (CHF). However, no one has documented the levels of ceramide itself in CHF or determined its potential prognostic value. METHODS: In this study we recruited patients with heart failure consecutively from the hospital, of whom 423 stable patients were eventually selected to participate in this study after an observation period of at least 3 months after hospital discharge. All patents were followed up for all-cause death to December 31, 2013. RESULTS: Plasma ceramide levels were increased stepwise with New York Heart Association functional class (I, 5.32 ± 1.98; II, 5.81 ± 1.63; III, 6.14 ± 2.14; IV, 6.66 ± 2.61 ng/mL). During a mean follow-up of 4.4 years (interquartile range: 3.5-5.3 years), a total of 200 CHFpatients died. The optimal threshold value of ceramide was 6.05 ng/mL. Ceramide levels as continuous and as dichotomous variables are risk factors for mortality in CHF (adjusted hazard ratio, 1.31; 95% confidence interval, 1.16-1.47; P < 0.001 and adjusted hazard ratio, 2.07, 95% confidence interval, 1.53-2.81; P < 0.001, respectively). When ceramide levels were combined with conventional CHF risk factors, the area under the curve increased from 0.68 (0.63-0.72) to 0.72 (0.68-0.76); P = 0.047. The continuous net reclassification index and integrated discrimination improvement index were 17.2% (5.0-29.9%; P = 0.027) and 0.04 (0.01-0.08; P = 0.020), respectively. CONCLUSIONS: Plasma ceramide levels were increased and correlated with the severity of CHF, and were an independent risk factor of mortality in patients with CHF and reduced left ventricular systolic function. Ceramide levels might provide additional predictive value after conventional risk assessment.
Authors: Yi Zhang; Yan Huang; Anna Cantalupo; Paula S Azevedo; Mauro Siragusa; Jacek Bielawski; Frank J Giordano; Annarita Di Lorenzo Journal: JCI Insight Date: 2016-04-21
Authors: Stanley M Walls; Anthony Cammarato; Dale A Chatfield; Karen Ocorr; Greg L Harris; Rolf Bodmer Journal: Cell Rep Date: 2018-03-06 Impact factor: 9.423
Authors: Yoav Hadas; Adam S Vincek; Elias Youssef; Magdalena M Żak; Elena Chepurko; Nishat Sultana; Mohammad Tofael Kabir Sharkar; Ningning Guo; Rinat Komargodski; Ann Anu Kurian; Keerat Kaur; Ajit Magadum; Anthony Fargnoli; Michael G Katz; Nadia Hossain; Ephraim Kenigsberg; Nicole C Dubois; Eric Schadt; Roger Hajjar; Efrat Eliyahu; Lior Zangi Journal: Circulation Date: 2020-01-29 Impact factor: 29.690
Authors: Iris D Zelnik; Giora Volpert; Leena E Viiri; Dimple Kauhanen; Tamar Arazi; Katriina Aalto-Setälä; Reijo Laaksonen; Anthony H Futerman Journal: J Lipid Res Date: 2020-07-10 Impact factor: 5.922